Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
Practical Radiation Oncology
|
November 27, 2014
Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer
Kristina Mirabeau-Beale, Theodore S Hong, Andrzej Niemierko, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 10, 2012
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang, Jianping Yuan, Elda Righi, et al.
Plos One
|
June 16, 2012
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer
Jeffrey A Meyerhardt, Marek Ancukiewicz, Thomas A Abrams, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 22, 2015
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer
Rebecca S Heist, Dan G Duda, Dushyant V Sahani, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 2, 2012
External beam accelerated partial-breast irradiation using 32 gy in 8 twice-daily fractions: 5-year results of a prospective study
Itai M Pashtan, Abram Recht, Marek Ancukiewicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 31, 2013
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study
Andrew X Zhu, Marek Ancukiewicz, Jeffrey G Supko, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 19, 2015
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Sara M Tolaney, Yves Boucher, Dan G Duda, et al.
Neuro-Oncology
|
July 6, 2013
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
Christine Lu-Emerson, Matija Snuderl, Nathaniel D Kirkpatrick, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 12, 2010
Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas
Sam S Yoon, Dan G Duda, Daniel L Karl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
Tracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
Practical Radiation Oncology
|
November 27, 2014
Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer
Kristina Mirabeau-Beale, Theodore S Hong, Andrzej Niemierko, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 10, 2012
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang, Jianping Yuan, Elda Righi, et al.
Plos One
|
June 16, 2012
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer
Jeffrey A Meyerhardt, Marek Ancukiewicz, Thomas A Abrams, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 22, 2015
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer
Rebecca S Heist, Dan G Duda, Dushyant V Sahani, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 2, 2012
External beam accelerated partial-breast irradiation using 32 gy in 8 twice-daily fractions: 5-year results of a prospective study
Itai M Pashtan, Abram Recht, Marek Ancukiewicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 31, 2013
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study
Andrew X Zhu, Marek Ancukiewicz, Jeffrey G Supko, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 19, 2015
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Sara M Tolaney, Yves Boucher, Dan G Duda, et al.
Neuro-Oncology
|
July 6, 2013
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
Christine Lu-Emerson, Matija Snuderl, Nathaniel D Kirkpatrick, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 12, 2010
Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas
Sam S Yoon, Dan G Duda, Daniel L Karl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
Tracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.
Page
of 9